Literature DB >> 22569236

Effects of adding exercise to a 16-week very low-calorie diet in obese, insulin-dependent type 2 diabetes mellitus patients.

Marieke Snel1, Amalia Gastaldelli, D Margriet Ouwens, Matthijs K C Hesselink, Gert Schaart, Emma Buzzigoli, Marijke Frölich, Johannes A Romijn, Hanno Pijl, A Edo Meinders, Ingrid M Jazet.   

Abstract

CONTEXT: Reduction of 50% excess body weight, using a very low-calorie diet (VLCD; 450 kcal/d) improves insulin sensitivity in obese type 2 diabetes mellitus patients.
OBJECTIVE: The objective of the study was to evaluate whether adding exercise to the VLCD has additional benefits.
DESIGN: This was a randomized intervention study.
SETTING: The study was conducted at a clinical research center in an academic medical center.
SUBJECTS: Twenty-seven obese [body mass index 37.2 ± 0.9 kg/m(2) (mean ± sem)] insulin-treated type 2 diabetes mellitus patients. INTERVENTION: Patients followed a 16-wk VLCD. Thirteen of them simultaneously participated in an exercise program (E) consisting of 1-h, in-hospital training and four 30-min training sessions on a cycloergometer weekly. OUTCOME MEASURES: Insulin resistance was measured by a hyperinsulinemic euglycemic clamp. Insulin signaling, mitochondrial DNA (mtDNA) content, and intramyocellular lipid content was measured in skeletal muscle biopsies.
RESULTS: Baseline characteristics were identical in both groups. Substantial weight loss occurred (-23.7 ± 1.7 kg VLCD-only vs. -27.2 ± 1.9 kg VLCD+E, P = NS within groups). The exercise group lost more fat mass. Insulin-stimulated glucose disposal increased similarly in both study groups [15.0 ± 0.9 to 39.2 ± 4.7 μmol/min(-1) · kg lean body mass (LBM(-1)) VLCD-only vs. 17.0 ± 1.0 to 37.5 ± 3.5 μmol/min(-1) · kg LBM(-1) in VLCD+E], as did phosphorylation of the phosphatidylinositol 3-kinase-protein kinase B/AKT insulin signaling pathway. In contrast, skeletal muscle mtDNA content increased only in the VLCD+E group (1211 ± 185 to 2288 ± 358, arbitrary units, P = 0.016 vs. 1397 ± 240 to 1196 ± 179, P = NS, VLCD-only group). Maximum aerobic capacity also only increased significantly in the VLCD+E group (+6.6 ± 1.7 ml/min(-1) · kg LBM(-1) vs. +0.7 ± 1.5 ml/min(-1) · kg LBM(-1) VLCD-only, P = 0.017).
CONCLUSION: Addition of exercise to a 16-wk VLCD induces more fat loss. Exercise augments maximum aerobic capacity and skeletal muscle mtDNA content. These changes are, however, not reflected in a higher insulin-stimulated glucose disposal rate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569236     DOI: 10.1210/jc.2011-3178

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training.

Authors:  Ricardo Augusto Leoni De Sousa; Alex Cleber Improta-Caria
Journal:  Metab Brain Dis       Date:  2022-01-25       Impact factor: 3.584

2.  Cross talk mechanisms of aerobic exercise training on obesity, type 2 diabetes, and Alzheimer's disease: the role of insulin resistance.

Authors:  Ricardo Augusto Leoni De Sousa; Caíque Olegário Diniz de Magalhães; Isabella Rocha Dias; Lucas Renan Sena de Oliveira; Alex Cleber Improta-Caria; Ricardo Cardoso Cassilhas
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-07       Impact factor: 1.712

3.  Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Authors:  Trevor Teich; Emily C Dunford; Deanna P Porras; Jacklyn A Pivovarov; Jacqueline L Beaudry; Hazel Hunt; Joseph K Belanoff; Michael C Riddell
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-03       Impact factor: 4.310

4.  Relationships between mitochondrial function and metabolic flexibility in type 2 diabetes mellitus.

Authors:  Tineke van de Weijer; Lauren Marie Sparks; Esther Phielix; Ruth Carla Meex; Noud Antonius van Herpen; Matthijs Karel C Hesselink; Patrick Schrauwen; Vera Bettina Schrauwen-Hinderling
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

5.  Outcomes and utilization of a low intensity workplace weight loss program.

Authors:  Kelly M Carpenter; Jennifer C Lovejoy; Jane M Lange; Jenny E Hapgood; Susan M Zbikowski
Journal:  J Obes       Date:  2014-01-02

6.  Formula food-reducing diets:A new evidence-based addition to the weight management tool box.

Authors:  A R Leeds
Journal:  Nutr Bull       Date:  2014-09

7.  Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers.

Authors:  Maria A Sleddering; Albert J Markvoort; Harish K Dharuri; Skhandhan Jeyakar; Marieke Snel; Peter Juhasz; Moira Lynch; Wade Hines; Xiaohong Li; Ingrid M Jazet; Aram Adourian; Peter A J Hilbers; Johannes W A Smit; Ko Willems Van Dijk
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

8.  Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus.

Authors:  A Goday; D Bellido; I Sajoux; A B Crujeiras; B Burguera; P P García-Luna; A Oleaga; B Moreno; F F Casanueva
Journal:  Nutr Diabetes       Date:  2016-09-19       Impact factor: 5.097

9.  The impact of duration on effectiveness of exercise, the implication for periodization of training and goal setting for individuals who are overfat, a meta-analysis.

Authors:  J E Clark
Journal:  Biol Sport       Date:  2016-08-05       Impact factor: 2.806

10.  Benefits of a Paleolithic diet with and without supervised exercise on fat mass, insulin sensitivity, and glycemic control: a randomized controlled trial in individuals with type 2 diabetes.

Authors:  Julia Otten; Andreas Stomby; Maria Waling; Andreas Isaksson; Anna Tellström; Lillemor Lundin-Olsson; Søren Brage; Mats Ryberg; Michael Svensson; Tommy Olsson
Journal:  Diabetes Metab Res Rev       Date:  2016-06-30       Impact factor: 4.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.